1,435 results on '"Gazzard Brian"'
Search Results
152. HIV DNA two long terminal repeat circles: observations and interpretations
153. Innate and adaptive immunological insights into HIV pathogenesis
154. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma
155. Bella and the blood sample
156. The diagnostic yield of stool analysis in 525 HIV-1-infected individuals
157. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma
158. Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection
159. Editorial
160. How does HAART lead to the resolution of Kaposiʼs sarcoma?
161. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma
162. Kaposi's sarcoma - an update
163. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART
164. Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy
165. HIV-related lung cancer in the era of highly active antiretroviral therapy
166. Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy
167. Passive immunization in ARC and AIDS
168. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma
169. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients
170. AIDS defining malignancies in the era of HAART
171. Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
172. A case of march fracture in a patient with osteoporosis on long-term HAART
173. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
174. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors
175. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis
176. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection
177. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
178. Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis
179. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
180. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
181. True gynaecomastia, another manifestation of immune reconstitution disease?
182. Reduced TH1/TH17 CD4 T-cell numbers are associated with impaired purified protein derivative–specific cytokine responses in patients with HIV-1 infection
183. Incidence and risk factors for the development of indinavir-associated renal complications
184. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
185. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
186. Cessation of secondary prophylaxis in patients with cryptococcosis
187. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors
188. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine
189. Development and application of a new measure of engagement in out‐patient HIV care
190. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor
191. The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1–infected “true” long-term nonprogressors
192. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use
193. Efficacy of a Nelfinavir- and Nevirapine-Containing Salvage Regimen
194. Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy
195. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic
196. Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel
197. A retrospective study of neutropenia in HIV disease
198. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex
199. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi‚s sarcoma
200. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.